OLEMA PHARMACEUTICALS INC. - COMMON STOCK

Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

22 Oct 2023 02:55:00 By Nasdaq GlobeNewswire

Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors

17 Oct 2023 07:01:00 By Nasdaq GlobeNewswire

Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress

16 Oct 2023 07:02:00 By Nasdaq GlobeNewswire

Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity

12 Oct 2023 07:01:00 By Nasdaq GlobeNewswire

Olema Oncology Announces Expansion of Collaboration Agreement with Novartis

10 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Oct 2023 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

20 Sep 2023 07:29:20 By Nasdaq GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences

06 Sep 2023 16:30:55 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Sep 2023 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology Announces Combined Financing for Up to $180 Million

05 Sep 2023 07:30:49 By Nasdaq GlobeNewswire

Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update

08 Aug 2023 16:03:07 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Aug 2023 16:30:34 By Nasdaq GlobeNewswire

Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference

01 Aug 2023 08:00:10 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Jul 2023 07:30:32 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Jun 2023 16:30:23 By Nasdaq GlobeNewswire

Olema Oncology to Present at the 2023 Jefferies Healthcare Conference

30 May 2023 16:30:43 By Nasdaq GlobeNewswire

Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study

11 May 2023 08:43:20 By Nasdaq GlobeNewswire

Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update

09 May 2023 16:01:03 By Nasdaq GlobeNewswire

Olema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual Congress

08 May 2023 07:06:10 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 May 2023 16:30:57 By Nasdaq GlobeNewswire